



- (51) **International Patent Classification:**
C07K 16/28 (2006.01) *A61P 35/00* (2006.01)
- (21) **International Application Number:**
PCT/US2021/035268
- (22) **International Filing Date:**
01 June 2021 (01.06.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/033,609 02 June 2020 (02.06.2020) US
- (71) **Applicant:** **ARCUS BIOSCIENCES, INC.** [US/US];
3928 Point Eden Way, Hayward, California 94545 (US).
- (72) **Inventors:** **GAUTHIER, Kelsey Sivick;** Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545 (US). **WALKER, Nigel Pelham Clinton;** Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545 (US). **ZHAO, Xiaoning;** Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545 (US). **LIPPINCOTT, John;** Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545 (US).
- (74) **Agent:** **KIM, Eunha** et al.; One Financial Center, Boston, Massachusetts 02111 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) **Title:** ANTIBODIES TO TIGIT

FIG. 10A





FIG. 10B



(57) **Abstract:** The present disclosure provides antibodies that specifically bind to TIGIT. The antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The antibodies can be used for treatment of cancer and infectious disease, among other applications.

[Continued on next page]

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))